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OBJECTIVES This study assessed the effects of carbenoxolone on human myocardial conduction and
refractoriness.
BACKGROUND Carbenoxolone, an antipeptic ulcer drug, has been shown to reduce gap junctional coupling
without affecting cellular ion channels. Gap junctions (GJ) are considered to be determinants
of cardiac action potential propagation. The effects of GJ uncoupling in the human heart are
unknown.
METHODS Right atrial (RA) and ventricular (RV) activation mapping (Carto, Biosense Webster Inc.,
Diamond Bar, California) was performed during sinus rhythm. Right atrial and RV wavefront
propagation velocity (WPV), specifically in the direction of propagation, was determined
from these maps using a triangulation method. Refractoriness at multiple RA and RV sites,
sinus rhythm cycle length, and AH, PR, QRS, and QT intervals were measured. The protocol
was repeated 1 h after oral administration of 100 mg of carbenoxolone.
RESULTS In 11 patients, WPV was reduced from 79.6  13.3 cm/s to 57.2  9.1 cm/s (27.1 
12.8%, p  0.001) in RA and from 98.7  19.8 cm/s to 76.5  21.7 cm/s (22.7  14.1%,
p  0.01) in RV after carbenoxolone. Conduction slowing was more marked in 6 older
patients with ischemic heart disease compared with younger subjects with normal hearts (RA
35.1  5.5% vs. 17.5  12.7%, p  0.03; RV 33.8  5.1% vs. 9.3  7.7%, p 
0.001). Refractoriness and electrocardiogram parameters remained unchanged.
CONCLUSIONS Carbenoxolone causes a 27% reduction in human RA WPV and 23% in the RV without
affecting refractoriness. The slowing of myocardial conduction by carbenoxolone demon-
strates the significance of GJ in regulating human myocardial conduction and provides a tool
for investigating the effects of GJ uncoupling on human arrhythmogenesis. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.093Cardiol 2006;48:1242–9) © 2006 by the American College of Cardiology Foundation
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Eap junctions are regions of membrane specialization be-
ween adjacent cells, forming clusters of intercellular com-
unication channels. These are, in turn, formed from
onnexins, a highly conserved family of membrane proteins
1). Human cardiomyocytes express connexins 40, 43, and
5. Gap junctions are important determinants of action
otential propagation in the myocardial syncytium.
Modification of connexin expression and modulation of
unction has been shown to alter conduction velocity in
enetically modified mice and other animal models, but
ever in the intact heart of a conscious animal (2–7).
lterations in connexin expression and distribution have
een documented in human cardiac disease in which there
re disturbances of conduction and arrhythmogenesis, such
s ischemia, hypertrophy, heart failure, and atrial fibrillation
8–12). We have previously demonstrated an association
etween connexin levels and human right atrial (RA)
onduction velocity (13). The effects of modulating gap
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Manuscript received January 3, 2006; revised manuscript received April 21, 2006,
ccepted April 25, 2006.unctional coupling in human myocardium have not been
etermined.
Carbenoxolone is a drug used previously in the treatment
f gastrointestinal ulceration and has been shown to reduce
ap-junctional coupling in mammalian myocardium with-
ut affecting the ion channels responsible for cardiac action
otential generation (14,15). We sought to address the
ypothesis that carbenoxolone could alter human atrial and
entricular conduction without affecting refractoriness. Such
vidence would establish the direct relationship between gap
unctional coupling and human myocardial conduction in
ivo.
ETHODS
atient selection. Studies were performed in patients un-
ergoing clinically indicated electrophysiology studies
EPS). All antiarrhythmic drugs were stopped 5 half lives
efore the study. No patient had received amiodarone at any
tage. All patients underwent coronary angiography and
chocardiography at least 24 h before EPS. The study was
pproved by the local research and ethics committee.
PS. The EPS was undertaken in the post-absorptive state
ith lidocaine used as local anesthesia. Two 7-F venous
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September 19, 2006:1242–9 Carbenoxolone and Cardiac Electrophysiologyheaths were introduced into the right femoral vein, and a
uadripolar catheter with 2-mm interelectrode spacing
Bard EP, Lowell, Massachusetts) was maneuvered to the
igh RA, distal coronary sinus (CS), and right ventricle
RV) to deliver programmed stimulation, and positioned in
stable position in the CS to provide reference electrograms
uring electroanatomical mapping.
Surface electrocardiogram (ECG) and bipolar endocar-
ial electrograms were monitored continuously and stored
n a digital amplifier/recorder system (Siemens EP, Mu-
ich, Germany) for offline analysis. Intracardiac electro-
rams were filtered from 30 to 500 Hz. The mean values of
0 consecutive measurements of PR, QRS, and QT inter-
als were taken from lead II with computer-assisted calipers
t a display speed of 200 mm/s; AH and PR intervals were
sed as markers of nodal conduction. QRS duration and
bsolute QT intervals were used as a measure of interven-
ricular conduction and ventricular repolarization, respec-
ively.
easurement of refractoriness. Absolute effective refrac-
ory periods (AERP) were assessed at 4 separate sites (high
A, distal CS, RV apex, and RV outflow tract) at 600 ms
nd 500 ms, at twice diastolic thresholds and pulse width of
.0 ms with an 8-beat drive train followed by a S2 extra-
timulus. Absolute effective refractory period was defined as
he longest S1-S2 coupling interval that resulted in failure of
ocal capture.
lectroanatomic mapping. The Carto system (Biosense
ebster Inc., Diamond Bar, California) has been described
n detail before (16,17). Briefly, global activation mapping
as recorded during a stable rhythm by point-to-point
cquisition of positions with reliable local activation times
LATs) and accurate 3-dimensional coordinates, gated to a
table reference CS electrogram. The maximum deflection
rom baseline of bipolar electrograms of each point defined
he LAT. If the bipolar electrograms have equivalent
aximum positive and negative deflections, the maximum
egative v/t of the unipolar electrogram was used to mark
he LAT (18). Signals were filtered between 1 and 240 Hz
or unipolar electrograms and between 30 and 400 Hz for
ipolar electrograms. Each point was acquired only if
nd-diastolic stability was 2 mm and the LAT stability
Abbreviations and Acronyms
AERP  absolute effective refractory period
CS  coronary sinus
EPS  electrophysiology studies
IHD  ischemic heart disease
LAT  local activation time
RA  right atrial/atrium
RV  right ventricle/ventricular
WPV  wavefront propagation velocityas 2 ms between 2 consecutive measurements, implying mstable catheter-wall contact. The superior, inferior vena
ava, and tricuspid annulus were tagged for anatomical
rientation; 214  98 points were analyzed per patient.
Isochronal activation maps were created for both RA and
V during sinus rhythm (Fig. 1). Sinus rhythm cycle length
as measured as the average of all preceding beat-to-beat
ntervals preceding each point acquired during mapping.
alculation of wavefront propagation velocity (WPV). Our
echniques of measuring the macroscopic rate at which a
avefront travels in the direction of propagation are based
n the principles of triangulation and have been previously
escribed (19,20). In brief, points in close proximity and
ctivated by the same wavefront but separated by a LAT of
ore than 3 ms apart from each chamber were grouped into
riads.
A triad of points would define a triangle in a single plane
Fig. 2). The difference in LATs and the distances between
hese points were used to measure the WPV.
Wavefront propagation velocity (Fig. 2):
v
OA
tOA
cos 
The distance between any 2 points in 3-dimensional
pace could be calculated using the formula:
OA  distance between O and A 
(xa x0)2 (ya y0)2 (za z0)2,
f O and A had the coordinates (x0, y0, z0) and (xa, ya, za),
espectively.
tOA was the difference in LAT between O and A, and
lpha was calculated by the trigonometric principles. In this
odel, conduction within each triad was assumed to be
niform, and chamber curvature was not taken into account.
hese potential inaccuracies were minimized by selecting
ultiple triads of points in regions of uniform isochronal
pacing with a mean interpoint distance of 7.4  3.9 mm.
oints within the earliest and latest isochrone of activation
ere not used to avoid the effects of multiple breakthrough
nd wavefront fusion.
epeat testing after carbenoxolone. Carbenoxolone (Bi-
rex, London, United Kingdom) has been used as a treat-
ent for peptic and oral ulceration since the 1960s at a dose
f 100 to 200 mg/day (21). Carbenoxolone is absorbed
apidly and unchanged from the stomach, reaching 90% of
heir peak (15 g/ml) within 40 min of oral administration
22). It is highly bound to plasma protein, with a long half
ife of about 19 h (23). In this study we aimed to test the
ffects of a single dose of 100 mg of carbenoxolone (1.42
g/kg in a 70-kg patient) on cardiac electrophysiology.
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Carbenoxolone and Cardiac Electrophysiology September 19, 2006:1242–9Patients were given a 100-mg oral dose of carbenoxolone.
fter a 60-min waiting period, the RA and RV were
e-mapped using the CARTO system as before, and pro-
rammed electrical stimulation to measure AERP was
epeated.
The same protocol was performed in control patients
xcept carbenoxolone was not administered. All patients
ad measurement of serum electrolytes at baseline, 1 and 4 h
fter ingestion of carbenoxolone.
tatistical analysis. Continuous data are presented as
ean and SD, and variables were analyzed using paired or
npaired t tests. Data analysis was performed using Prism
igure 1. Three-dimensional isochronal maps of the right atrium and vent
ight atrial activation (right lateral projection) before and after administrati
inus node (red) and propagates in a craniocaudal direction with broad, fairl
eft and right images show earliest right ventricular activation initiating fro
ass with broad wavefronts and latest activation being seen around the t
dministration of carbenoxolone, in keeping with the slowing of conducti.0 statistical software (Item Software, Hampshire, United dingdom). Statistical significance was defined as a proba-
ility value of 0.05.
ESULTS
atient population. Carbenoxolone was administered to
1 patients, age 60.8  15.1 years. Patient characteristics
re displayed in Table 1. Six patients (Patients #1 to #6) had
history of ischemic heart disease (IHD) with previous
evascularization procedures (either angioplasty or coronary
rtery bypass grafting) and impaired left ventricular systolic
unction (mean ejection fraction 36.0 11.6%) The other 5
atients were younger and had structurally normal hearts
rom Patient #4 during sinus rhythm. The top left and right images show
carbenoxolone, respectively. Atrial activation initiates in the region of the
orm wavefronts. The area of latest activation is shown in blue. The bottom
ltiple sites of breakthrough around the apex (red), activating the ventricular
id annulus (blue). A subjective crowding of isochrones can be seen afterricle f
on of
y unif
m mu
ricusp
on.emonstrated by echocardiography (mean ejection fraction
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September 19, 2006:1242–9 Carbenoxolone and Cardiac Electrophysiologyf 67.7  10.8%) and absence of coronary artery disease as
hown by angiography.
ffects of carbenoxolone on WPVs. Baseline WPV in
he RA was 79.6  13.3 cm/s, which decreased to 57.2 
.1 cm/s (27.1  12.8% reduction, p  0.001) after
dministration of carbenoxolone. In the RV, mean WPV
ecreased from 98.7  19.8 cm/s to 76.5  21.7 m/s
22.7  14.1% reduction, p  0.01) in the RV after
arbenoxolone (Fig. 3).
A greater reduction in WPV after carbenoxolone was
een in the 6 older patients with IHD compared with the 5
Figure 2. Schematic representation of a triad of 3 endocardial poin
able 1. Clinical Characteristics of Patients
Patients Age Gender Coronary Artery Disease
EF
(%)
1 71 M Previous anterior MI, PCI to LAD 51
2 64 M Previous inferior MI, CABG for
3-vessel disease
23
3 71 M Previous anterior MI, PCI to first
diagonal
45
4 57 M Previous anterior and inferior MI,
PCI to RCA and LAD
30
5 77 M Previous inferior MI, CABG for
3-vessel disease
42
6 67 M Previous anterior MI, CABG for
3-vessel disease
25
7 43 F None 79
8 47 F None 78
9 55 M None 66
10 83 F None 60
11 34 F None 55
ABG  coronary artery bypass graft; EF  left ventricular ejection fraction; EPS 
rtery; LVDD left ventricular end-diastolic dimension; MI myocardial infarction; PCI
ardiac death; VT  ventricular tachycardia.atients with structurally normal hearts (Fig. 4). In patients
ith IHD, mean RAWPV decreased by 35.1 5.5%, from
5.8  15.8 cm/s to 55.0  6.8 cm/s (p  0.001), whereas
n patients without IHD, mean RA WPV fell by 17.5 
2.7%, from 72.3  3.0 cm/s to 59.8  11.5 cm/s (p 
.04). This differential reduction in RA WPV was statisti-
ally significant (p  0.03), although the 2 groups were not
atched in age or gender. Similarly, in the RV of IHD
ubjects, WPV decreased by 33.8 5.1%, from 97.4 24.7
m/s to 63.8  12.8 cm/s (p  0.01), whereas in patients
ithout IHD, RV WPV declined by 9.3  7.7%, from
rked as O, A, and B. v represents wavefront propagation velocity.
DD
m)
LA
(mm) Indications for EPS Results of EPS
1.3 44.7 Non-sustained VT VT induced
2.0 49.0 Sustained VT VT induced
2.2 42.2 Non-sustained VT Non-inducible study
7.0 41.3 Syncope Non-inducible study
2.0 38.6 Syncope, non-sustained VT Non-inducible study
8.5 46.3 Syncope, non-sustained VT VT induced
8.3 34.5 Syncope, non-sustained VT Non-inducible study
1.0 34.2 Syncope, non-sustained VT Non-inducible study
8.4 36.0 Syncope, non-sustained VT Non-inducible study
4.6 40.1 Palpitations, non-sustained VT Non-inducible study
1.1 35.3 Aborted SCD Non-inducible study
rophysiological studies; LA  left atrial dimension; LAD  left anterior descendingts, maLV
(m
7
7
6
6
5
6
4
4
4
4
4
elect
 percutaneous coronary intervention; RCA right coronary artery; SCD sudden
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Carbenoxolone and Cardiac Electrophysiology September 19, 2006:1242–900.4  14.5 cm/s to 91.8  20.8 cm/s (p  0.05). This
ifferential reduction in RV WPV was also statistically
ignificant (p  0.001). Sinus rhythm cycle lengths (832 
56 ms at baseline) did not change with carbenoxolone
823  150 ms, p  NS).
In 3 control patients with IHD (mean age of 57 years),
A and RV WPV measured from activation maps taken 60
in apart remained unchanged (RA WPV 77.1  11.0
m/s, RV WPV 92.4  5.2 cm/s at baseline; RA WPV
4.3  8.5, RV WPV 93.8  7.3 cm/s after 60 min of
aiting time, p  NS).
ffects of carbenoxolone on refractoriness. There were
o significant differences between AERP measurements at
igh RA, distal CS, RV apex, and RV outflow tract before
nd after carbenoxolone at both cycle lengths (Fig. 5).
ffects of carbenoxolone on ECG parameters and nodal
onduction. The PR, AH, and QRS intervals were not
ffected by the carbenoxolone (pre- vs. post-carbenoxolone:
R interval 183  27 vs. 178  28 ms, AH interval 112 
3 vs. 96  41 ms, QRS duration 103  29 vs. 105  31
s, QT interval 384  26 vs. 389  31 ms; all p  NS).
ffects of carbenoxolone on serum electrolytes. Admin-
stration of carbenoxolone did not significantly change
erum electrolytes. Baseline serum sodium, potassium, and
reatinine levels were 137.6  1.3 mEq/l, 4.0  0.3 mEq/l,
nd 1.15  0.21 mg/dl, respectively. After 4 h, serum
odium, potassium, and creatinine levels were 138.5  1.8
Eq/l, 4.0  0.3 mEq/l, and 1.15  0.21 mg/dl, respec-
igure 3. Effects of carbenoxolone (CARB) on myocardial wavefront
ropagation velocities (WPVs).ively (all p  NS).
p
pISCUSSION
n the intact human heart, carbenoxolone profoundly slows
oth atrial and ventricular WPVs, an effect most likely due
o gap junctional uncoupling. The degree of slowing was
ore marked in patients with IHD. Sinus node automatic-
ty, atrioventricular nodal function, refractoriness, and ven-
ricular repolarization appeared unchanged.
Although transgenic murine models of selective connexin
eletion provide a body of evidence that gap junctions are
mportant determinants of cardiac conduction, and we have
reviously demonstrated a relationship between the relative
xpression of naturally occurring connexins and human
trial conduction velocities, the current study provides
vidence that modulation of gap junctional function can
odify human cardiac conduction velocity (2,3,13).
ffects of carbenoxolone in animal models. Derivatives of
lycyrrhetinic acid, a ubiquitous compound in licorice root,
ere shown to inhibit gap junctional communication be-
ween human fibroblasts (24). One such derivative, carben-
xolone, reversibly blocked intercellular dye transfer be-
ween Cx43-transfected glioma cells in conjunction with a
eduction, but not complete loss of junctional conductance
s measured by dual cell voltage clamps (25). In this study,
apid onset and offset of changes in gap junctional conduc-
ance occurred without any changes to connexin 43 expres-
ion, phosphorylation, or localization.
When applied to isolated rabbit atrial and ventricular
yocytes, carbenoxolone did not affect action potential
haracteristics or ionic currents, namely IK, IK1, and Ito1,
-type calcium and sodium currents (14). In a Langerdoff-
erfused model of intact rabbit hearts, RA and left ventric-
lar conduction were significantly slowed after perfusion
ith carbenoxolone, which completely recovered with wash-
igure 4. Greater degree of atrial and ventricular conduction slowing in
atients with a history of ischemic heart disease (IHD). WPV wavefront
ropagation velocity.
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September 19, 2006:1242–9 Carbenoxolone and Cardiac Electrophysiologyut. We have shown that carbenoxolone slows atrial and
entricular conduction in guinea pigs by increasing intercel-
ular resistivity without affecting action potential parame-
ers, an effect that suggests that carbenoxolone specifically
ncouples cardiac gap junctions without affecting ion chan-
els responsible for the action potential profile (15).
Although a few experiments on neural tissue have sug-
ested that the effects of carbenoxolone may not solely be
ue to acute gap junctional closure, but rather through
on-specific actions on a variety of ion channels, no changes
o action potential profile or major ionic channel currents
ccur in cardiac tissue (14,15,26–29). Furthermore, the
rofound differences between neural and cardiac electro-
hysiology including the complexity of neural activity with
pontaneous oscillations occurring simultaneously at varying
requencies and dependence on synaptic chemotransmission
or neural action potential propagation limits the extent to
hich observations in neural tissue are relevant to cardiac
lectrophysiology.
arbenoxolone in human myocardium. Our current study
ought to determine whether carbenoxolone would slow con-
uction without affecting action potential duration, manifested
s the refractory period in the human heart. The absence of an
ffect of carbenoxolone on ion channel function and action
otential properties in cell culture and intact tissue studies,
oupled with an absence of change in refractory periods in the
ntact human heart, provides evidence that carbenoxolone at
hese doses does not affect the cardiac action potential gener-
tion (14,15). In accordance with this, the findings of un-
hanged maximum velocity upstroke of the action potential in
nimal models and the universal finding of slowing of conduc-
ion in rabbit, guinea pig, and human myocardium strongly
mplicates gap junctional uncoupling (14,15). The reversibility
f these findings coupled with the absence of quantitative
hanges in connexin protein is supportive of functional changes
n gap junctional activity rather than changes in protein
xpression or transcription (14,25). The absence of any changes
n the sinus rhythm cycle length after administration of
arbenoxolone in the current study would suggest that carben-
igure 5. Effects of carbenoxolone on cardiac refractoriness at 600 ms.
RA  high right atrium; RVA  right ventricular apex; RVOT  righxolone has no effect on sinus node automaticity and that the sbserved differences in atrial and ventricular conduction were
ot confounded by a change in sinus rhythm cycle length.
referential effects in patients with IHD. Ischemia leads
o the development of various concurrent biophysical
hanges such as acidosis and calcium overload, which could
ndividually result in gap junctional uncoupling (30). While
hese changes may cumulatively confer a physiologically
eneficial effect of limiting infarct size by decreasing the
ntercellular transmission of chemical mediators of injury, it
xacerbates electrical uncoupling (31). Computer models
uggest that while a decrease in gap junctional uncoupling
nly modestly affects conduction in regions of high conduc-
ance, a similar reduction in uncoupling in regions of
nitially lower gap junctional conductance would lead to
ignificant conduction slowing and possibly even electrical
solation (32–34). Hence, in the presence of a gap junctional
locker, a greater degree of conduction slowing might be
xpected in already poorly uncoupled tissue such as previ-
usly ischemic myocardium, and the greater reduction of
PV in patients with IHD is consistent with this concept.
he validity of our observations of a differential effect of
arbenoxolone in IHD patients is confounded by the fact
hat the IHD and non-IHD groups were not age-matched.
The disparity between significant myocardial slowing but
he lack of conduction delay in the specialized conducting
issue needs further clarification. While atrioventricular delay
as seen in murine and rabbit models after administration of
arbenoxolone, we did not find any such changes in both
easures of atrioventricular nodal conduction, namely PR and
H intervals. This discrepancy is most likely dose-related
lthough the influence of interspecies differences in the relative
evels of connexins 40, 43, and 45 coexpression cannot be
xcluded (35). Similarly, slowing of ventricular electrical prop-
gation without altering QRS durations in this cohort could be
ue to a lack of effect on the specialized conducting His-
urkinje system. Both strains of mice with connexin 40 or 43
eletion demonstrate significant QRS prolongation compared
ith littermate control mice, despite the absence of connexin
0 expression in ventricular myocardium. Therefore, the ob-
P  absolute effective refractory period; DCS  distal coronary sinus;
tricular outflow tract.AERerved QRS widening is most likely resultant of slowing
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Carbenoxolone and Cardiac Electrophysiology September 19, 2006:1242–9onduction within the His-Purkinje system, rather than ven-
ricular myocardium (4–7).
odulation of gap junctional function as a novel anti-
rrhythmic strategy? Conventional antiarrhythmic drugs
ct by modifying the ion channels responsible for myocar-
ial action potential generation, but by this action on
iseased myocardium, all existing antiarrhythmic drugs are
rone to cause ventricular arrhythmias. This renders them
argely unsuitable for the long-term treatment of arrhyth-
ias in the diseased heart and provides significant impetus
or developing fundamentally different approaches to the
harmacologic suppression of arrhythmias. Commonly used
ntiarrhythmic drugs have little or no effect on gap junc-
ional conductance (36). Because many disease states that
redispose to arrhythmias are known to substantially affect
ap junction expression and function, drugs that selectively
arget gap junctions and preferentially affect diseased myo-
ardium offer the potential for a novel antiarrhythmic
trategy. Although enhancement of gap junctional function
s likely to be the preferred therapeutic strategy, carbenox-
lone provides a useful tool that has not only demonstrated
he direct relationship between gap junctional function and
onduction and how this may be modified by myocardial
isease, but will also help explore the effects of gap junc-
ional modulation on clinical arrhythmogenesis.
tudy limitations. The IHD group was not age-matched to
he non-IHD group. Therefore, it is possible that the greater
egree of conduction slowing seen in patients with IHD may
e an age-dependent effect. Nevertheless, conduction slowing
as demonstrated in all patients, regardless of a history of IHD
Fig. 3). The time course, dose-response relationship, and
egree of gap junctional uncoupling in both myocardium and
pecialized conducting tissues could not be assessed due to the
onstraints of human clinical research.
onclusions. Carbenoxolone slows atrial and ventricular
PVs without affecting refractoriness or ventricular repo-
arization. The degree of conduction slowing is more
rofound in an older group of patients with IHD. Slowing
f conduction by carbenoxolone provides direct evidence for
he role of gap junctions in regulating human conduction.
eprint requests and correspondence: Dr. Prapa Kanagarat-
am, Department of Cardiology, St. Mary’s Hospital,
raed Street, London W2 1NY, United Kingdom. E-mail:
.kanagaratnam@imperial.ac.uk.
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